OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+47.65%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$600M
AUM Growth
+$600M
(+37%)
Cap. Flow
+$6.02M
Cap. Flow
% of AUM
1%
Top 10 Holdings %
Top 10 Hldgs %
72.6%
Holding
57
New
6
Increased
11
Reduced
18
Closed
13
Top Buys
| 1 |
Arvinas
ARVN
|
$17.2M |
| 2 |
Codexis
CDXS
|
$16.4M |
| 3 |
Liquidia Corp
LQDA
|
$13.7M |
| 4 |
Ginkgo Bioworks
DNA
|
$6.68M |
| 5 |
Zentalis Pharmaceuticals
ZNTL
|
$3.56M |
Top Sells
| 1 |
Catalyst Pharmaceutical
CPRX
|
$10.5M |
| 2 |
4D Molecular Therapeutics
FDMT
|
$7.26M |
| 3 |
Iovance Biotherapeutics
IOVA
|
$7.19M |
| 4 |
Cytokinetics
CYTK
|
$6.5M |
| 5 |
Intellia Therapeutics
NTLA
|
$4.88M |
Sector Composition
| 1 | Healthcare | 98.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Cytokinetics
CYTK
$5.98B
| $3.98M | 0.66% |
75,300
-123,200
| -62% | -$6.5M |
|
27
Gossamer Bio
GOSS
$587M
| $3.71M | 0.62% |
3,665,010
-244,990
| -6% | -$248K |
|
|
28
Zentalis Pharmaceuticals
ZNTL
$123M
| $3.56M | 0.59% |
+967,000
| New | +$3.56M |
|
29
Protara Therapeutics
TARA
$125M
| $3.08M | 0.51% |
1,681,154
-623,108
| -27% | -$1.14M |
|
30
Rezolute
RZLT
$630M
| $2.26M | 0.38% |
+466,563
| New | +$2.26M |
|
|
31
Catalyst Pharmaceutical
CPRX
$2.42B
| $2.24M | 0.37% |
112,500
-527,500
| -82% | -$10.5M |
|
32
AbCellera Biologics
ABCL
$1.19B
| $2.08M | 0.35% |
800,000
+600,000
| +300% | +$1.56M |
|
33
Lyell Immunopharma
LYEL
$220M
| $1.93M | 0.32% |
1,395,000
-275,000
| -16% | -$380K |
|
|
ALLK
34
DELISTED
Allakos
ALLK
| $1.57M | 0.26% |
2,407,600
-372,400
| -13% | -$243K |
|
35
Relmada Therapeutics
RLMD
$48.8M
| $1.56M | 0.26% |
480,000
-120,000
| -20% | -$389K |
|
36
PepGen
PEPG
$39M
| $1.53M | 0.26% |
+179,200
| New | +$1.53M |
|
|
RVNC
37
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.43M | 0.24% |
+275,000
| New | +$1.43M |
|
|
SYRS
38
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $1.41M | 0.23% |
654,943
-210,500
| -24% | -$453K |
|
|
JBIO
39
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $920K | 0.15% |
440,000
| – | – |
|
|
RGLS
40
DELISTED
Regulus Therapeutics
RGLS
| $840K | 0.14% |
535,000
-940,000
| -64% | -$1.48M |
|
41
iBio
IBIO
$16.9M
| $833K | 0.14% |
375,000
| – | – |
|
|
ADGM
42
Adagio Medical Holdings, Inc Common Stock
ADGM
$25.2M
| $285K | 0.05% |
+110,571
| New | +$285K |
|
|
OKUR
43
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| – | – |
-165,000
| Closed | -$249K |
|
44
Ventyx Biosciences
VTYX
$184M
| – | – |
-1,190,000
| Closed | -$2.75M |
|
45
Verastem
VSTM
$585M
| – | – |
-915,000
| Closed | -$2.73M |
|
46
Savara
SVRA
$591M
| – | – |
-714,960
| Closed | -$2.88M |
|
47
PMV Pharmaceuticals
PMVP
$82.1M
| – | – |
-475,000
| Closed | -$770K |
|
|
48
Intellia Therapeutics
NTLA
$1.26B
| – | – |
-218,000
| Closed | -$4.88M |
|
49
Lexicon Pharmaceuticals
LXRX
$392M
| – | – |
-1,875,000
| Closed | -$3.15M |
|
50
Karyopharm Therapeutics
KPTI
$61.4M
| – | – |
-1,425,000
| Closed | -$1.24M |
|